On August 7th, Zaiding Pharmaceutical announced that its net product revenue for the second quarter of 2024 was $100.1 million, compared to $68.9 million for the same period in 2023, a year-on-year increase of 45%, and a year-on-year increase of 47% calculated at a fixed exchange rate.
Zaiding Pharmaceutical stated that the growth in performance this time is mainly due to the increase in sales of Weiweijia after its listing in September 2023 and inclusion in the national medical insurance drug catalog in January 2024, as well as the sales growth of Zele and Nizhena.
Among them, the product revenue of Zele in the second quarter of 2024 was 45 million US dollars, and in the same period of 2023 it was 43 million US dollars, a year-on-year increase of 5%. This is mainly due to the increase in in-hospital sales of first-line maintenance therapy for ovarian cancer, the increase in treatment duration, and the successful renewal of the indications of Zele for first-line maintenance therapy for adult ovarian cancer and platinum sensitive recurrent ovarian cancer maintenance therapy under national medical insurance, which will take effect on January 1, 2024.
Weiweijia's product revenue in the second quarter of 2024 was $23.2 million, compared to $100000 in the same period of 2023, mainly due to its inclusion in the national medical insurance catalog for the treatment of generalized myasthenia gravis (gMG) starting from January 1, 2024, positive feedback from doctors and patients, and increased patient accessibility with Weiweijia's admission to the hospital. Weiweijia will be launched in September 2023 for the treatment of gMG.
In the second quarter of 2024, the product revenue of Nizh é le was $12.3 million, compared to $4.6 million in the same period of 2023, a year-on-year increase of 165%. This was mainly due to the inclusion of Nizh é le intravenous injection in the first quarter of 2023 for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and the inclusion of oral dosage forms for the above indications in the first quarter of 2024.